search
Back to results

Luna Interbody System for Fusion Trial (LIFT)

Primary Purpose

Lower Back Pain, Degenerative Disc Disease (DDD)

Status
Unknown status
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Spinal fusion
Sponsored by
Benvenue Medical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lower Back Pain focused on measuring Back pain, Spinal fusion, Degenerative disc disease (DDD), Lower back pain, Fusion

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 - 65 at the time of consent
  2. Patient has back pain consistent with symptomatic degenerative disc disease at one level or two contiguous levels from L2-S1 requiring surgical intervention.
  3. Patient has had at least 6 months of non-operative care
  4. Patient is mentally capable and willing to sign a study-specific informed consent form
  5. Patient is willing and able to comply with all study requirements
  6. Patient has a score on the back pain visual analog scale (VAS) of ≥ 40 mm
  7. Patient has an Oswestry Disability Index (ODI) score of ≥ 30%

Exclusion Criteria:

  1. DDD affecting >2 levels
  2. Back pain due to causes other than DDD
  3. Spine surgery within last 3 months or planned spine surgery within 6 weeks of post study procedure
  4. >Grade 1 spondylolisthesis or retrolisthesis
  5. Infection at or close to target disc level
  6. Active systemic infection
  7. Patient has known osteoporosis
  8. Prior interbody fusion at the target level
  9. Prior failed interbody fusion at any level
  10. Known allergy to device materials
  11. Uncontrolled psychiatric illness or severe dementia
  12. Pregnant at time of enrollment or considering getting pregnant during study period
  13. Any metabolic or other bone disease that could significantly compromise pedicle screw and/or interbody device placement.
  14. Any severe illness that would prevent complete study participation
  15. Uncontrolled diabetes
  16. Current use of chronic steroids (more than equivalent of 10 mg prednisone daily)
  17. Contraindication to spinal surgery or general anesthesia
  18. Coagulopathy
  19. Body mass index >35
  20. Current smoker
  21. Known illicit substance abuser
  22. Currently participating in another investigational study that could affect responses to the study device

Sites / Locations

  • Clinique du Parc Leopold
  • Hôpital Erasme
  • CHC Liege
  • Universitatsklinikum Bonn
  • Paracelsus Kliniken

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Luna Interbody System

Arm Description

Outcomes

Primary Outcome Measures

Proportion of subjects with device in place showing lack of device migration or subsidence and absence of device related serious adverse event
Improvement in pain score on the Visual Analog Scale (VAS) from baseline
Maintenance or improvement of neurologic function related to the spine
Proportion of subjects with lack of revision, removal, reoperation or use of additional supplemental fixation
Improvement in Oswestry Disability Index (ODI) score from baseline

Secondary Outcome Measures

Improvement from baseline in quality of life as measured by SF-36
Rate of device-related serious adverse events
Proportion of subjects with radiographic fusion of target segments

Full Information

First Posted
February 2, 2012
Last Updated
September 18, 2014
Sponsor
Benvenue Medical, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01551901
Brief Title
Luna Interbody System for Fusion Trial
Acronym
LIFT
Official Title
LIFT: Luna Interbody System for Fusion Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2012 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Benvenue Medical, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this trial is to evaluate the performance, safety and effectiveness of the Luna system for the treatment of degenerative disc disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lower Back Pain, Degenerative Disc Disease (DDD)
Keywords
Back pain, Spinal fusion, Degenerative disc disease (DDD), Lower back pain, Fusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Luna Interbody System
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Spinal fusion
Other Intervention Name(s)
Luna Interbody System
Intervention Description
Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
Primary Outcome Measure Information:
Title
Proportion of subjects with device in place showing lack of device migration or subsidence and absence of device related serious adverse event
Time Frame
12 Month Post-op
Title
Improvement in pain score on the Visual Analog Scale (VAS) from baseline
Time Frame
12 Month Post-op
Title
Maintenance or improvement of neurologic function related to the spine
Time Frame
12 Month Post-op
Title
Proportion of subjects with lack of revision, removal, reoperation or use of additional supplemental fixation
Time Frame
12 Month Post-op
Title
Improvement in Oswestry Disability Index (ODI) score from baseline
Time Frame
12 Month Post-op
Secondary Outcome Measure Information:
Title
Improvement from baseline in quality of life as measured by SF-36
Time Frame
12 Month Post-op
Title
Rate of device-related serious adverse events
Time Frame
12 Month Post-op
Title
Proportion of subjects with radiographic fusion of target segments
Time Frame
12 Month Post-op

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 - 65 at the time of consent Patient has back pain consistent with symptomatic degenerative disc disease at one level or two contiguous levels from L2-S1 requiring surgical intervention. Patient has had at least 6 months of non-operative care Patient is mentally capable and willing to sign a study-specific informed consent form Patient is willing and able to comply with all study requirements Patient has a score on the back pain visual analog scale (VAS) of ≥ 40 mm Patient has an Oswestry Disability Index (ODI) score of ≥ 30% Exclusion Criteria: DDD affecting >2 levels Back pain due to causes other than DDD Spine surgery within last 3 months or planned spine surgery within 6 weeks of post study procedure >Grade 1 spondylolisthesis or retrolisthesis Infection at or close to target disc level Active systemic infection Patient has known osteoporosis Prior interbody fusion at the target level Prior failed interbody fusion at any level Known allergy to device materials Uncontrolled psychiatric illness or severe dementia Pregnant at time of enrollment or considering getting pregnant during study period Any metabolic or other bone disease that could significantly compromise pedicle screw and/or interbody device placement. Any severe illness that would prevent complete study participation Uncontrolled diabetes Current use of chronic steroids (more than equivalent of 10 mg prednisone daily) Contraindication to spinal surgery or general anesthesia Coagulopathy Body mass index >35 Current smoker Known illicit substance abuser Currently participating in another investigational study that could affect responses to the study device
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alphonse Lubansu, M.D.
Organizational Affiliation
Hôpital Erasme
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique du Parc Leopold
City
Bruxelles
ZIP/Postal Code
1040
Country
Belgium
Facility Name
Hôpital Erasme
City
Bruxelles
ZIP/Postal Code
1070
Country
Belgium
Facility Name
CHC Liege
City
Liege
Country
Belgium
Facility Name
Universitatsklinikum Bonn
City
Bonn
ZIP/Postal Code
53105
Country
Germany
Facility Name
Paracelsus Kliniken
City
Zwickau
ZIP/Postal Code
08008
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Luna Interbody System for Fusion Trial

We'll reach out to this number within 24 hrs